Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | +4.88% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.78 | N/A | +4.88% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter but emphasized their commitment to ongoing research and development. They did not provide specific guidance, indicating uncertainty about future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their clinical programs despite the current financial results.
The earnings report highlights ongoing challenges for Revolution Medicines, particularly in generating revenue. The stock's significant drop of 11.82% reflects investor disappointment, especially given the lack of guidance. The company is focusing on its clinical programs, but without clear financial expectations, uncertainty remains high.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
May 6, 2022